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Abstract: The goal of this study was to investigate the potential for a cannabidiol-rich cannabis
extract (CRCE) to interact with the most common over-the-counter drug and the major known cause
of drug-induced liver injury–acetaminophen (APAP)–in aged female CD-1 mice. Gavaging mice
with 116 mg/kg of cannabidiol (CBD) [mouse equivalent dose (MED) of 10 mg/kg of CBD] in
CRCE delivered with sesame oil for three consecutive days followed by intraperitoneally (i.p.)
acetaminophen (APAP) administration (400 mg/kg) on day 4 resulted in overt toxicity with 37.5%
mortality. No mortality was observed in mice treated with 290 mg/kg of CBD+APAP (MED of 25 mg/kg
of CBD) or APAP alone. Following CRCE/APAP co-administration, microscopic examination revealed
a sinusoidal obstruction syndrome-like liver injury–the severity of which correlated with the degree
of alterations in physiological and clinical biochemistry end points. Mechanistically, glutathione
depletion and oxidative stress were observed between the APAP-only and co-administration groups,
but co-administration resulted in much greater activation of c-Jun N-terminal kinase (JNK). Strikingly,
these effects were not observed in mice gavaged with 290 mg/kg CBD in CRCE followed by APAP
administration. These findings highlight the potential for CBD/drug interactions, and reveal an
interesting paradoxical effect of CBD/APAP-induced hepatotoxicity.
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1. Introduction
Cannabidiol (CBD) is one of the major phytocannabinoids in Cannabis sativa that has seen
a dramatic increase in popularity over recent years due to expanded availability and aggressive
marketing. Though CBD is regarded as lacking psychotropic activity, it does display a number
of neuropharmacological effects, including anti-seizure activity. CBD, as the prescription drug
EPIDIOLEX®, recently received the US Food and Drug Administration (FDA) approval, with
indications for treatment of certain severe forms of epilepsy [1,2]. Although that makes it a regulated
drug in some forms, it is still widely marketed in an array of over-the-counter products in variable
forms, and touted as a treatment for various medical conditions ranging from depression to arthritis
and cancer [3,4].
Emerging evidence, however, indicates that CBD poses a significant risk for hepatotoxicity.
A number of animal studies have reported increased liver weights, elevation of liver enzymes and
bilirubin in circulation as well as molecular signatures of hepatotoxicity after administration of CBD or
cannabidiol-rich cannabis extract (CRCE) [5–7]. In clinical trials, elevated liver enzymes were observed
in 5–20% of patients treated with CBD, and several patients were withdrawn due to the threat of liver
failure [1,2,8].
Evolving evidence suggests that CBD has the potential to induce drug interactions, involving
the modulation of various cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes
responsible for xenobiotic metabolism [7,9–11]. CBD was shown to modulate CYP2E1 and CYP1A2,
two of the more common P450 enzymes involved in drug metabolism and drug-induced hepatotoxicity
(e.g., acetaminophen (APAP) and ethanol). Such an interaction potential is especially concerning among
the elderly, as CYP activity and drug clearance are known to be impaired with age [12,13]. Furthermore,
rates of drugs use increase with age, with the highest overall prevalence observed in older women, of
whom 94% take at least 1 medication, and 57% take 5 or more medications [14]. Lastly, recent research
indicates that herbal dietary supplements pose a greater risk for hepatotoxicity among women (with
similar patterns observed in female mice) [15–17]. Therefore, the goal of this study was to investigate
the CBD/APAP interaction potential in aged female CD-1 mice.
2. Results and Discussion
2.1. Overt Toxicity Associated with CRCE/APAP Administration
Female, 9 month old, CD1 mice were gavaged over three consecutive days with vehicle, 116,
or 290 mg/kg CBD. On the fourth day, mice were injected with either PBS or 400 mg/kg APAP.
Three of the mice treated with 116 mg/kg CBD + APAP (n = 8) succumbed within 5 h of APAP dosing.
No mortality was observed in the 290 mg/kg CBD+APAP or Veh+APAP mice. Mice in the CBD+APAP
groups developed a sub-lethargic condition which was characterized by a substantial decrease in
activity, nuzzling into bedding material, impaired response to external stimuli, and a decrease in body
temperature. Veh+APAP mice developed hypothermia only.
Fluctuations in body weights were observed in mice among all experimental groups; however,
in 116 mg/kg CBD+APAP mice there were statistically significant decreases in body weights (−4%,
p < 0.05) (Supplementary Figure S1A). Furthermore, significant increases in liver-to- body weight (LBW)
ratios were observed in 116 mg/kg CBD + APAP (p < 0.01) (Supplementary Figure S1B). No significant
differences were observed in heart-or kidney-to-body weight ratios (Supplementary Figure S1C,D).
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2.2. CRCE/APAP Cause Acute Liver Injury
Histopathological evaluation of liver samples revealed abnormalities in the 116 mg/kg CBD+APAP
mice manifested as a sinusoidal obstruction syndrome, or SOS, pattern of injury (Figure 1). Specifically,
diffuse, centrivenular-dominant regions of sinusoidal dilation accompanied by marked vascular
congestion, hepatic plate atrophy, and centrivenular necrosis were observed in the livers of six mice in
this group (Table 1). However, foci of sinusoidal destruction were observed in the livers of only two
out of eight mice in 290 mg/kg CBD + APAP and one out of seven mice in the Veh+APAP group.
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Figure 1. Co-administration of cannabidiol-rich cannabis extract (CRCE) and APAP results in
sinusoid obstructive syndrome-like histomorphological alterations in the livers of aged female CD-1
mice. H&E stained liver sections from (A) vehicle-gavaged mice (sesame oil), (B) 116 mg/kg CBD,
(C) 290 mg/kg CBD, (D) APAP (400 mg/kg), (E) 116 mg/kg CBD+APAP, (F) 290 mg/kg CBD+APAP.
Black brackets indicate areas of clear cell changes (D), yellow brackets (E) and arrows (F) indicate areas
of sinusoidal dilation with vascular congestion, and blue arrows (E) indicate areas of hepatic plate
atrophy. CRCE—cannabidiol-rich cannabis extract; APAP—acetaminophen. Magnification: X10.
Table 1. Histopathological evaluation of mouse livers using a modified Rubbia-Brandt sinusoid
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mg/kg) (n = 7)
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+ APAP (n = 8)
CBD, 290mg/kg
+ APAP (n = 8)
Sinusoidal dilation 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.9 ± 0.4 2.0 ± 0.5 * 0.8 ± 0.5
Venous obstruction 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Atrophy 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.3 ± 0.2 0.6 ± 0.2 0.3 ± 0.2
Apoptosis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.1





mg/kg (n = 7)
CBD, 290
mg/kg (n = 8)
APAP (400
mg/kg) (n = 7)
CBD, 116 mg/kg
+ APAP (n = 8)
CBD, 290mg/kg
+ APAP (n = 8)
Necrosis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.6 2.0 ± 0.6 * 0.8 ± 0.4
Microvesicular steatosis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Small droplet steatosis 1.0 ± 0.3 0.7 ± 0.4 0.6 ± 0.3 0.3 ± 0.3 1.0 ± 0.3 1.1 ± 0.3
Large droplet steatosis 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
Clear cell changes 0.0 ± 0.0 0.3 ± 0.3 0.8 ± 0.3 1.4 ± 0.4 0.6 ± 0.4 1.3 ± 0.5
Portal inflammation 0.2 ± 0.1 0.0 ± 0.0 0.1 ± 0.1 0.0 ±0.0 0.5 ± 0.4 0.0 ± 0.0
Lobular inflammation 0.9 ± 0.2 1.2 ± 0.3 0.8 ± 0.2 0.6 ± 0.2 1.4 ± 0.6 0.8 ± 0.2
Interface activity 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.4 0.0 ± 0.0
Scores between vehicle and APAP groups at each dose of CBD were analyzed with a Mann-Whitney test and a
Bonferroni correction for multiple comparisons. Significance was therefore determined at α ≤ 0.0167. Data presented
as average scores for each parameter ± SEM with an * indicating a significant difference between vehicle and APAP
groups at the corresponding dose of CBD. Liver samples of all experimental animals (n = 45) were evaluated.
Details on scoring parameters are provided in the Supplementary Materials and Methods Section.
No significant differences were observed in the serum levels of total bilirubin and AST in
experimental mice. This was likely due, in part, to the fact that serum samples were not available
from deceased animals in the 116 mg/kg CBD + APAP group, nor from several moribund mice whose
condition precluded adequate blood volume withdrawal. However, elevated serum levels of ALT
were observed in 116 mg/kg CBD+APAP mice, compared to the control mice (Figure 2), and the extent
of alterations in physiological (body weight, LBW) and clinical biochemistry endpoints significantly
correlated with the degree of liver injury (Table 2).
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Figure 2. Effects of CRCE/APAP co-administration on commonly assessed clinical chemistry parameters
for liver injury. Blood was collected at the time of sacrifice, and the serum was subsequently separated
and removed for analysis. Veh (n = 7); Veh + APAP (n = 7); 116 mg/kg CBD (n = 7); 116 mg/kg
CBD+APAP (n = 5); 290 mg/kg CBD (n = 7); 290 mg/kg CBD + APAP (n = 6). Data are presented
as mean ± SEM (* p < 0.05). ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP:
alkaline phosphatase; GGT: gamma-glutamyl transferase.
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Table 2. List-wise format of each of the 15 unique correlations in the correlation matrix.
Row Column Correlation p-Value
Liver-to-body weight ratio Bilirubin 0.37 0.0210
Liver-to-body weight ratio Total GSH −0.17 0.3897
Liver-to-body weight ratio GSSG/GSH 0.28 0.1465
Liver-to-body weight ratio Sinusoidal dilation 0.42 0.0065
Liver-to-body weight ratio Necrosis 0.56 0.0002
Bilirubin Total GSH −0.49 0.0043
Bilirubin GSSG/GSH 0.48 0.0054
Bilirubin Sinusoidal dilation 0.61 <0.0001
Bilirubin Necrosis 0.67 <0.0001
Total GSH GSSG/GSH −0.69 <0.0001
Total GSH Sinusoidal dilation −0.75 <0.0001
Total GSH Necrosis −0.70 <0.0001
GSSG/GSH Sinusoidal dilation 0.74 <0.0001
GSSG/GSH Necrosis 0.71 <0.0001
Sinusoidal dilation Necrosis 0.86 <0.0001
2.3. Molecular Alterations Associated with CRCE/APAP
To gain insight into the mechanisms of CBD-induced exacerbation of APAP hepatotoxicity, we
first measured expression of a panel of genes involved in the metabolism of CBD and APAP. APAP
itself did not cause substantial changes in mRNA levels in any of the investigated genes, except for
Ugt1a6 and Ugt2a3 transferases (Figure 2). However, dose-dependent increases in the expression of
numerous CYPs and UGTs were observed in the CBD treated mice. Furthermore, the CBD + APAP
group had increased expression of Cyp2b10, and a strong interaction effect was observed in the case of
Cyp2e1 after 290 mg/kg CBD + APAP, but not after 116 mg/kg CBD + APAP (Figure 3).
Molecules 2019, 24, 2256 6 of 12
Molecules 2019, 24, x FOR PEER REVIEW 6 of 12 
 
 
Figure 3. Effects of CRCE/APAP co-administration on intrahepatic expression of cytochrome P450s 
and UDP-glucuronosyltransferases. Livers were collected 5 h after APAP administration and gene 
expression was measured using the quantitative real-time (qRT) PCR. Veh (n = 7); Veh + APAP (n = 
7); 116 mg/kg CBD (n = 7); 116 mg/kg CBD + APAP (n = 7); 290 mg/kg CBD (n = 8); 290 mg/kg CBD + 
APAP (n = 8). Data presented as mean ± SEM fold changed from vehicle (*, p < 0.05; **, p < 0.01; ***, p 
< 0.001; and ****p < 0.0001). The following genes were changed significantly with either CBD or APAP, 
but the two-way ANOVA did not yield any significant comparisons: Cyp2d22 (APAP, p = 0.0016), 
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Figure 3. Effects of CRCE/APAP co-administration on intrahepatic expression of cytochrome P450s
and UDP-glucuronosyltransferases. Livers were collected 5 h after APAP administration and gene
expression was measured using the quantitative real-time (qRT) PCR. Veh (n = 7); Veh + APAP (n = 7);
116 mg/kg CBD (n = 7); 116 mg/kg CBD + APAP (n = 7); 290 mg/kg CBD (n = 8); 290 mg/kg CBD
+ APAP (n = 8). Data presented as mean ± SEM fold changed from vehicle (* p < 0.05; ** p < 0.01;
*** p < 0.001; and **** p < 0.0001). The following genes were changed significantly with either CBD or
APAP, but the two-way ANOVA did not yield any significant comparisons: Cyp2d22 (APAP, p = 0.0016),
Ugt1a1 (CBD, p = 0.0186; APAP, p = 0.0255), Ugt1a6 (CBD, p = 0.0222), and Ugt1a9 (APAP, p = 0.0026).
2.4. Mechanisms of CRCE/APAP-Induced Liver Injury
Metabolism of APAP to the reactive metabolite (N-acetyl-p-benzoquinone imine; NAPQI) through
the CYP P450s, especially CYP2E1, is well recognized for its role in the initiation of toxicity [18].
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Because of the robust increase in Cyp2e1 mRNA levels observed in the 290 mg/kg CBD + APAP group,
we hypothesized that CBD increases metabolism and bioactivation of APAP. Therefore, we measured
acetaminophen protein adducts levels (APAP-CYS), a generally recognized biomarker of APAP
exposure linked to the formation of toxic NAPQI. APAP-CYS were increased in the APAP treated
mice. However, no difference in APAP–CYS were observed among the Veh + APAP, compared to
the 116 mg/kg CBD+APAP and 290 mg/kg CBD+APAP mice (Figure 4A). Furthermore, there was no
correlation between the degree of liver injury observed in the mice and the amount of APAP-CYS.
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Figure 4. Mechanisms of CRCE/APAP-induced liver injury. (A) APAP-Cys protein adducts; levels of (B)
GSH, and (C) GSSG/ SH; (D) mRNA levels of Gclm as easured by quantitative real-time (qRT) PCR;
E) protein levels of Jnk and pJNK as measured by Western blot; and F) representative blot. Veh (n = 7);
Veh + APAP (n = 7); 116 mg/kg CBD (n = 7); 116 mg/kg CBD + APAP (n = 7); 290 mg/kg CBD (n = 8);
290 mg/kg CBD + APAP (n = 8). Data presented as m an ± SEM fold changed from vehicl (* p < 0.05;
** p . 1; and **** p < 0.0001). GSSG levels wer significantly affected by APAP (p = 0.0151), but there
are no significant comparisons.
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APAP depletes hepatic glutathione very early in the time course of APAP toxicity (e.g., 1 h) in the
mouse, and re-synthesis occurs after 4 h [19]. Glutathione depletion causes oxidative stress and also
contributes to SOS [20]. At 5 h, hepatic GSH was not statistically different in the Veh + APAP mice
(although trend towards reduction was observed), but was significantly reduced in the mice receiving
116 mg/kg CBD + APAP (Figure 4B). In mice administered 290 mg/kg CBD + APAP, an unexpected and
rapid re-synthesis of glutathione was observed, in which total glutathione approximated that observed
in control mice (Figure 4B). Interestingly, the GSSG/GSH ratio, an indicator of liver redox status, was
spiked in 116 mg/kg CBD+APAP, but not in the other groups (Figure 4C). Furthermore, the highest
GSSG/GSH values–indicative of an overwhelming state of oxidative liver stress–were observed in mice
characterized by the highest degree of histopathological, physiological, and biochemical end-points of
liver injury (Table 2).
To further confirm these findings, we performed mRNA analysis of Gclm, one of the rate-limiting
enzymes for glutathione re-synthesis, and determined protein levels of phosphorylated JNK, which
is known to be activated by oxidative stress. Consistent with histopathological, physiological and
clinical biochemistry data, significant increases in Gclm expression were observed in the vehicle +
APAP and 290 mg/kg CBD + APAP groups, suggesting rapid re-synthesis of glutathione (Figure 4D).
However, expression of Gclm was not induced in the 116 mg/kg CBD + APAP mice, indicating that the
normal response to enhance re-synthesis of glutathione was impaired. Lastly, we observed increased
JNK phosphorylation in 116 mg/kg CBD+APAP mice (Figure 3E,F). Taken together, these data are
consistent with the hypothesis that 116 mg/kg CBD enhanced overall toxicity by increasing hepatic
JNK activation and impairing glutathione synthesis.
3. Conclusions
Here, for the first time, the in vivo potential for a CBD/drug interaction resulting in liver injury has
been demonstrated. Treatment of mice with clinically relevant CBD doses in CRCE for three consecutive
days, followed by a challenge with APAP, resulted in the development of an SOS-like pattern of
liver injury and mortality, neither of which were observed in the Veh + APAP group. Mechanistically,
the observed effect was associated with an overwhelming oxidative catastrophe triggered by massive
oxidative stress, rapid depletion of liver glutathione, impaired glutathione re-synthesis, and greater
JNK activation. Of particular concern, this effect was observed after administration of the lower,
116 mg/kg, CBD dose in CRCE (i.e., MED = 10 mg/kg). Further studies are clearly needed to investigate
this paradoxical effect and its mechanisms.
Congruent with the results of our study, emerging evidence suggests that CBD creates a significant
drug interaction that could lead to serious adverse health effects, including liver injury. For instance,
in a recent clinical trial, combining CBD with valproic acid led to a more robust elevation in liver
enzymes, such that liver transaminases were ≥3 times the upper limit of normal in 17% of patients [21].
Our data corroborate recent clinical observations regarding CBD hepatotoxicity and caution against its
casual, non-medically supervised usage with potentially hepatotoxic medications.
4. Materials and Methods
4.1. CBD Extract Characterization, Dosing Solution and Dose Calculations
Cannabidiol-rich cannabis extract (CRCE) was prepared at the University of Mississippi’s National
Center for Natural Product Research by extraction of CBD rich cannabis plant material (5.61% of CBD
and 0.2% THC) using hexane as the extraction solvent. The extract was then evaporated to dryness,
followed by raising the temperature to 80 ◦C to affect complete decarboxylation of the extract.
Phytochemical analysis of CRCE showed the following: cannabidiol content–57.9%; other
cannabinoids: cannabichromene–2.03%, ∆9-tetrahydrocannabinol–1.69%, cannabigerol–1.07%,
∆8-tetrahydrocannabinol–<0.01%; tetrahydrocannabivarin–<0.01%. The residual solvent was <0.5%;
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loss on drying–0.32%; heavy metals: lead, mercury, cadmium, and arsenic–not detected; aflatoxins:
AFB1, AFB2, AGF1, AFG2–not detected.
CRCE dose was calculated based on CBD content in the characterized extract to deliver the required
dose of CBD. The extract was diluted in sesame oil to prepare the gavage solution. Allometric scaling
for CBD mouse equivalent doses (MED) was determined per the recommendation of Wojcikowski and
Gobe which, in turn, is based upon the FDA Industry Guidance for Estimating the Maximum Safe
Starting Dose in Initial Clinical Trials for Therapeutics in Adult Volunteers [22]. The scaling factor of
11.6, commonly used for mice weighing between 36–50 g, was used to calculate the MED for CBD,
using the lowest recommended human maintenance dose of CBD (10 mg/kg EPIDIOLEX®). Thus, 1X
and 2.5X MED doses consisted of 5.104 mg total CBD (116 mg/kg) and 18.45 mg total CBD (290 mg/kg
respectively, delivered in 300 µL of gavage CRCE solution in sesame oil. Similar doses were used in
our previous 2-week repeated dosing study on CBD and were not associated with hepatotoxicity [7].
Control mice received 300 µL of sesame oil.
4.2. Animals
Nulliparous female CD-1 mice were purchased from Charles River (Wilmington, MA, USA) and
aged at the University of Arkansas for Medical Sciences (UAMS) Division of Laboratory Animal
Medicine (DLAM) facility. We used outbred mice in order to mimic the genetic heterogeneity of humans.
At 9 months of age, mice were randomly assigned to the following groups: control (n = 7), 116 mg/kg
CBD (n = 7), 290 mg/kg CBD (n = 8), APAP (400 mg/kg; n = 7), 116 mg/kg CBD + APAP (n = 8), and
290 mg/kg CBD + APAP (n=8). APAP was purchased from Sigma (St. Louis, MO, USA; >98% purity).
Mice were gavaged with CRCE for three consecutive days at 0800, followed by i.p. injection of APAP
(400 mg/kg) dissolved in warm PBS on day 4. With this experimental setup, we sought to mimic
conventional usage of CBD followed by ingestion of a high dose of APAP, a likely scenario given the
popularity of both compounds. Animals were euthanized 5 h after APAP administration. To avoid any
potential fasting-exacerbated toxicity, food and water were provided ad libitum. All procedures were
approved by the UAMS Institutional Animal Care and Use Committee (protocol number: AUP #3701).
4.3. Blood Sampling and Clinical Biochemistry
Blood was collected from the retro-orbital plexus with a heparinized micro-hematocrit capillary
tube (Fisher Scientific, Pittsburg, PA, USA) and placed into a 1.1 mL Z-gel microtube (Sarstedt, Newton,
NC, USA). Tubes were kept on ice prior to centrifugation at 10,000 rpm for 20 min; serum samples were
delivered to the Veterinary Diagnostic Laboratory at the Arkansas Livestock and Poultry Commission
(Little Rock, AR, USA) for further analysis.
4.4. Histopathological Assessment
Liver sections were fixed in 4% formalin and processed at the UAMS Pathology Core Facility.
Two independent, blinded pathologists evaluated the hematoxylin eosin sections at 20×, 40×, 100×,
200×, and 400×magnification, as described in Supplementary Materials and Methods.
4.5. Analysis of mRNA Levels of Major Cytochromes and Transporter Genes
Total RNA was extracted from flash frozen liver tissue using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). Following purification, 1000 ng were reverse transcribed with the High
Capacity cDNA Reverse Transcription Kit (ThermoFisher, Waltham, MA, USA). Primers were added at
a final concentration of 5 µM (Supplementary Table S1). Gene expression values were calculated as
fold change from control according to the ∆∆CT method.
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4.6. Analysis of the APAP Protein Adducts in the Liver Tissue
APAP-protein adducts were measured as previously described, with modifications [23,24].
Details are provided in Supplementary Materials and Methods.
4.7. Glutathione Analysis
Hepatic glutathione was measured using a modified Tietze assay [25] as described in
Supplementary Materials and Methods.
4.8. Western Blot
Protein levels for JNK and pJNK were measured by western blot, as previously described [26].
4.9. Statistical Analysis
Data were analyzed with either Graphpad Prism 6 software (Graphpad Software, San Diego, CA,
USA) or R (The R Foundation). The primary contrasts of interest were Vehicle + APAP at CBD doses
of 0, 116, and 290 mg/kg for each of the measured study parameters. A 2 × 3 factorial arrangement
of treatments analysis of variance model was fit to each response variable. Next, the above three
contrasts were computed using a Bonferroni correction to assure a 95% family-wise confidence level.
Interaction effects were evaluated using a two-way ANOVA. Bonferrroni adjusted p-values were also
computed. Histology scores were analyzed with a Mann-Whitney test comparing vehicle versus APAP
at each CBD dose. p-values were adjusted with a Bonferroni correction (3 comparisons for α ≤ 0.0167).
Response variables were also analyzed for correlation using Spearman’s Rank Correlation due to
non-continuous data in the histological analyses.
Supplementary Materials: The following are available online, Table S1: Forward and reverse primer sequences
for cytochrome P450s and UDP-gluconosyltrasferases, Figure S1: Changes in body weight and organ-to-body
weight ratios after CBD ± APAP, Figure S2: Clinical chemistry parameters in the serum of experimental mice.
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